| Symbol | NRXP |
|---|---|
| Name | NRX PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1201 ORANGE STREET,SUITE 600, WILMINGTON, Delaware, 19801, United States |
| Telephone | +1 484 - 254-6134 |
| Fax | — |
| — | |
| Website | https://nrxpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001719406 |
| Description | NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour. Additional info from NASDAQ: |
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
Read moreFDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval
Read more(85% Positive) NRX PHARMACEUTICALS, INC. (NRXP) Announces Clinical Development Update
Read moreNRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
Read moreKadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition
Read moreZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics
Read moreNRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
Read moreNRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
Read more(99% Neutral) NRX PHARMACEUTICALS, INC. (NRXP) Announces Clinical Development Update
Read moreNRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option
Read more| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| KX2-391 | DRUG | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT01397799 |
| Oraxol | DRUG | Phase PHASE1 | Solid Tumor | COMPLETED | NCT01967043 |
| Metronidazole | DRUG | Phase PHASE1 | Bacterial Infections | COMPLETED | NCT03332732 |
| VNRX-5022 | DRUG | Phase PHASE1 | Bacterial Infections | COMPLETED | NCT03332732 |
| VNRX-5133 | DRUG | Phase PHASE1 | Bacterial Infections | COMPLETED | NCT02955459 |
| VNRX-5133 and VNRX-5022 | DRUG | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT03690362 |
| VNRX-5133 + cefepime | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT03870490 |
| Nivolumab | DRUG | Phase PHASE1 | Advanced Hepatocellular Carcinoma | TERMINATED | NCT03059147 |
| SF1126 | DRUG | Phase PHASE1 | Advanced or Metastatic Solid Tumors | COMPLETED | NCT00907205 |
| ceftibuten | DRUG | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT06665555 |
| ledaborbactam etzadroxil | DRUG | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT06665555 |
| Meropenem | DRUG | Phase PHASE3 | Ventilator-associated Pneumonia | WITHDRAWN | NCT06168734 |
| Cefepime-taniborbactam | DRUG | Phase PHASE3 | Ventilator-associated Pneumonia | WITHDRAWN | NCT06168734 |
| cefepime-taniborbactam | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT04951505 |
| VNRX-5024 (ceftibuten) | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT04877379 |
| Placebo for VNRX-5024 | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT04314206 |
| VNRX-5024 | DRUG | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT04314206 |
| Placebo | DRUG | Phase PHASE1 | Bacterial Infections | COMPLETED | NCT02955459 |
| Placebo for VNRX-9945 | DRUG | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT04845321 |
| VNRX-9945 | DRUG | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT04845321 |
| Esomeprazole | DRUG | Phase PHASE1 | Healthy Volunteer | ACTIVE_NOT_RECRUITING | NCT06733675 |
| Ceftibuten-ledaborbactam etzadroxil | DRUG | Phase PHASE1 | Healthy Volunteer | ACTIVE_NOT_RECRUITING | NCT06733675 |
| Ledaborbactam etzadroxil | DRUG | Phase PHASE1 | Healthy Volunteer | ACTIVE_NOT_RECRUITING | NCT06733675 |
| Ceftibuten | DRUG | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT05488678 |
| VNRX-7145 | DRUG | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT05488678 |